Proteomics International Laboratories Ltd. ( (AU:PIQ) ) has provided an announcement.
Proteomics International Laboratories Ltd announced that its subsidiary, OxiDx Pty Ltd, has secured a second-generation Australian patent for its OxiDx oxidative stress diagnostic test, which is valid until 2039. The test, which uses a simple fingerprick blood sample to detect oxidative stress, is gaining interest from sectors such as high-performance sports and horse racing. The company plans to launch the test in Australia in mid-2025 and subsequently expand into the US. This patent strengthens the commercial value of the OxiDx technology, which is already protected in the USA, Japan, and Europe, and pending in other jurisdictions. The OxiDx test is significant as oxidative stress is linked to over 70 health conditions, including muscle injuries that account for a substantial portion of sports injuries.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd, based in Perth, Western Australia, is a medical technology company specializing in precision diagnostics and bio-analytical services, with a focus on proteomics. The company aims to enhance the quality of life by developing innovative tools for improved disease treatment.
YTD Price Performance: -38.12%
Average Trading Volume: 167,626
Technical Sentiment Signal: Buy
Current Market Cap: A$64.85M
For a thorough assessment of PIQ stock, go to TipRanks’ Stock Analysis page.